Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) (JAK1/JAK2)

Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) are intracellular non-receptor tyrosine kinases that serve as critical mediators in the JAK-STAT signaling pathway (Source: UniProt). They function by phosphorylating Signal Transducers and Activators of Transcription (STAT) proteins in response to cytokine or growth factor binding to cell surface receptors (Source: NIH). JAK1 is primarily associated with the signaling of pro-inflammatory cytokines like IL-6 and interferons, whereas JAK2 is essential for the action of hematopoietic growth factors such as erythropoietin and thrombopoietin (Source: StatPearls). Dysregulation of these kinases, including the JAK2 V617F mutation, is a key driver in myeloproliferative neoplasms and various autoimmune diseases like rheumatoid arthritis (Source: PubMed). Drugs such as ruxolitinib and baricitinib are designed to inhibit these kinases, thereby reducing inflammation and abnormal cell proliferation (Source: PubChem). However, the dual inhibition of JAK1 and JAK2 can lead to significant safety concerns, most notably hematologic toxicities like anemia due to the suppression of JAK2-mediated erythropoiesis (Source: FDA). Additionally, clinical use is monitored for risks of serious infections, cardiovascular events, and thrombosis (Source: NIH).

Other names

JAK1JAK2Janus kinase 1Janus kinase 2JAK1/2JAK1/JAK2

ATP-competitive inhibition of the JAK1 and JAK2 kinase domains, preventing the phosphorylation of STAT proteins and subsequent nuclear translocation for gene transcription.